


## Edatrexate

Cat. No.:	HY-13617
CAS No.:	80576-83-6
Molecular Formula:	C <sub>22</sub> H <sub>25</sub> N <sub>7</sub> O <sub>5</sub>
Molecular Weight:	467.48
Target:	Antifolate
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is <a href="#">Methotrexate</a> (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck <sup>[1][2]</sup> .								
<b>In Vivo</b>	<p>Edatrexate (0.14 g/kg and 0.21 g/kg; i.p.; twice weekly×3 or weekly×3) exerts potent efficacy against advanced metastatic disease in tumor-bearing mice, better than MTX<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma)<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.14 g/kg and 0.21 g/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment</td> </tr> <tr> <td>Result:</td> <td>Increased survival of tumor-bearing mice. Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue.</td> </tr> </table>	Animal Model:	Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma) <sup>[2]</sup>	Dosage:	0.14 g/kg and 0.21 g/kg	Administration:	Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment	Result:	Increased survival of tumor-bearing mice. Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue.
Animal Model:	Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma) <sup>[2]</sup>								
Dosage:	0.14 g/kg and 0.21 g/kg								
Administration:	Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment								
Result:	Increased survival of tumor-bearing mice. Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue.								

### REFERENCES

[1]. Grant SC, et al. Edatrexate, an antifolate with antitumor activity: a review. *Cancer Invest.* 1993;11(1):36-45.

[2]. Sirotnak FM, et al. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors. *Cancer Res.* 1993 Feb 1;53(3):587-91.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA